SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9]

Référence GTX632604-25ul

Conditionnement : 25ul

Marque : Genetex

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunoprecipitation (IP). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Flow cytometry (FACS). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC-P (cell pellet) (IHC-P (cell pellet)). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC (Paraffin sections) (IHC-P). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC (Paraffin sections) (IHC-P). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC-P (cell pellet) (IHC-P (cell pellet)). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC (Paraffin sections) (IHC-P). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604

Host

Mouse

Clonality

Monoclonal

Clone Name

1A9

Isotype

IgG1

Application

WB, ICC/IF, IHC-P, IHC-Fr, FACS, IP, ELISA, EM, Neutralizing/Inhibition, Sandwich ELISA, IHC-P (cell pellet)

Reactivity

SARS Coronavirus, SARS Coronavirus 2
Package
100 μl,
25 μl
View product citations for antibody GTX632604 on CiteAb

APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Recommended Dilution
WB 1:500-1:3000
ICC/IF 1:100-1:2000
IHC-P 1:100-1:500
IHC-Fr Assay dependent
FACS Assay dependent
IP Assay dependent
ELISA Assay dependent
EM Assay dependent
Neutralizing/Inhibition Assay dependent
Sandwich ELISA Assay dependent
IHC-P (cell pellet) Assay dependent

Note :

IHC-P
Recommended heat-Induced Epitope Retrieval pH 6.0 for 20 minutes.

Sandwich ELISA
Capture : GTX632604, Detection: GTX635654 / GTX135356 / GTX635672 / GTX135386 / GTX135360 / GTX635910 / GTX635911 / GTX635693 / GTX635792 / GTX635793 / GTX635713.
Recommend using GTX400033 (Trident RIPA Lysis Buffer with low SDS) as dilution buffer for diluting samples and antibodies in sandwich ELISA assay if including GTX632604 as capture antibody.

Not tested in other applications.

Product Note

This antibody detects both SARS-CoV spike and SARS-CoV-2 spike proteins (S2 subunit). Based on sequence analysis, this antibody is predicted to recognize S2' subunit. Our internal testing indicates no cross-reactivity with MERS-CoV spike protein.This antibody is able to detect multiple SARS-CoV-2 VOCs, including Omicron variant.

PROPERTIES

Form

Liquid

Buffer

PBS

Preservative

No preservative

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Concentration

1 mg/ml (Please refer to the vial label for the specific concentration.)

Antigen Species

SARS Coronavirus

Immunogen

The immunogen used to generate this antibody corresponds to SARS-CoV SΔ10 (within S2 domain) protein (1029-1192 a.a.). (SARS-CoV strain: Sin2774) The exact sequence is proprietary.

Purification

Affinity purified by Protein G.

Conjugation

Unconjugated

RRID

AB_2864418

Note

For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.

TARGET

Synonyms

2019-nCoV Spike , SARS-CoV-2 Spike , COVID-19 Spike

DATA IMAGES

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604

GTX632604 ICC/IF Image

SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] detects SARS-CoV-2 (COVID-19) spike protein by immunofluorescent analysis.
Sample: BHK-21 cells transfected with full-length SARS-CoV-2 spike were fixed in 4% paraformaldehyde at RT for 30 min.
Green: SARS-CoV-2 (COVID-19) spike stained by SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:2000.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant full-length SARS-CoV-2 spike (trimer) protein using GTX632604 as capture antibody at concentration of 5 μg/mL and GTX635672 as detection antibody at concentration of 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis was performed by coating the plate with recombinant SARS-CoV-2 (COVID-19) Spike (ECD) Protein, Omicron / BA.2.12.1 variant, His tag (GTX137114-pro) (28.62-0.45 nM). Coated protein was probed with the specified SARS-CoV-2 (COVID-19) Spike antibodies (1 μg/mL). Goat anti-rabbit IgG antibody (HRP) (GTX213110-01) (1:10000) or goat anti-mouse IgG antibody (HRP) (GTX213111-01) (1:10000) were used to detect the bound primary antibodies.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis was performed by coating the plate with recombinant SARS-CoV-2 spike (ECD) trimer, omicron BA.2.75 variant, His tag (GTX137533-pro) (28.62-0.45 nM). Coated protein was probed with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (the specified SARS-CoV-2 (COVID-19) Spike antibodies) (1 μg/mL). Goat anti-mouse IgG antibody (HRP) (GTX213111-01) (1:10000) was used to detect the bound primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunoprecipitation (IP). GTX632604

GTX632604 IP Image

Immunoprecipitation of SARS-CoV-2 Spike transfected 293T whole cell extracts using 2 μg of SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604).
Western blot analysis was performed using SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604).
EasyBlot HRP-conjugated anti mouse IgG antibody (GTX221667-01) was used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of non-transfected (GTX535673) and SARS-CoV-2 spike (full length) transfected (GTX535664) 293T whole cell extracts using GTX632604 as capture antibody at concentration of 5 μg/mL and GTX135356 as detection antibody at concentration of 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis was performed by coating the plate with recombinant SARS-CoV-2 (COVID-19) Spike (ECD) Protein, BA.2 / Omicron variant, His tag (GTX137037-pro) (29.71-0.46 nM). Coated protein was probed with the specified SARS-CoV-2 (COVID-19) Spike antibodies (1 μg/mL). Goat anti-rabbit IgG antibody (HRP) (GTX213110-01) (1:10000) or goat anti-mouse IgG antibody (HRP) (GTX213111-01) (1:10000) were used to detect the bound primary antibodies.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604

GTX632604 WB Image

Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:5000. The HRP-conjugated anti-mouse IgG antibody (GTX213111-01) was used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604

GTX632604 WB Image

Non-infected (–) and infected (+, 48h pl MOI 0.01) Caco-2 whole cell extracts were separated by SDS-PAGE, and the membrane was blotted with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:1000.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis was performed by coating plate with 50 μL of recombinant SARS-CoV-2 (COVID-19) spike S2 ECD protein at concentrations ranging from 0.0625 μg/mL to 4 μg/mL. The coated protein is detected with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) at 1 μg/mL. Mouse IgG antibody (HRP) (GTX213111-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis was performed by coating the plate with recombinant SARS-CoV-2 (COVID-19) Spike (ECD) Protein, Omicron / BF.7 variant, His tag (GTX137880-pro) (28.78-0.45 nM). Coated protein was probed with the specified SARS-CoV-2 (COVID-19) Spike antibodies (1 μg/mL). Goat anti-rabbit IgG antibody (HRP) (GTX213110-01) (1:10000) or goat anti-mouse IgG antibody (HRP) (GTX213111-01) (1:10000) was used to detect the bound primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis was performed by coating the plate with recombinant SARS-CoV-2 (COVID-19) Spike (ECD) Protein, Omicron / BQ.1 variant, His tag (GTX137881-pro) (28.78-0.45 nM). Coated protein was probed with the specified SARS-CoV-2 (COVID-19) Spike antibodies (1 μg/mL). Goat anti-rabbit IgG antibody (HRP) (GTX213110-01) (1:10000) or goat anti-mouse IgG antibody (HRP) (GTX213111-01) (1:10000) was used to detect the bound primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Flow cytometry (FACS). GTX632604

GTX632604 FACS Image

FACS analysis of 293T cells infected with recombinant vaccinia virus carrying the Spike gene using GTX632604 SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9].

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 (COVID-19) Spike S2 (ECD) protein, mouse IgG Fc tag protein (GTX135684-pro) using SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) as capture antibody at concentration of 5 μg/mL and SARS-CoV-2 (COVID-19) Spike S2 antibody [HL237] (GTX635693) as detection antibody at concentration of 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC-P (cell pellet) (IHC-P (cell pellet)). GTX632604

GTX632604 IHC-P (cell pellet) Image

SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] detects SARS-CoV-2 (COVID-19) spike protein by immunohistochemical analysis.
Sample: Mock (GTX435670) and SARS-CoV-2 (COVID-19) Spike transfected 293T cell FFPE Cell Pellet Block (GTX435640).
Red: SARS-CoV-2 (COVID-19) spike stained by SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:1000.
Blue: Fluoroshield with DAPI (GTX30920).
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant Spike ECD protein(s) derived from different strains of SARS-CoV-2 virus (ie., Wild type; B.1.1.7 alpha variant; B.1.351 beta variant; P.1 gamma variant; B1.617.2 delta variant) using antibodies as below.

Capture: SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (5 μg/mL)
Detection: SARS-CoV-2 (COVID-19) Spike S1 antibody [HL13402] (GTX635713) (1 μg/mL)

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of non-transfected (GTX535673) and SARS-CoV-2 spike (full length) transfected (GTX535664) 293T whole cell extracts using SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) as capture antibody at concentration of 5 μg/mL and SARS-CoV-2 (COVID-19) Spike S1 antibody [HL6] (GTX635654) as detection antibody at concentration of 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC (Paraffin sections) (IHC-P). GTX632604

GTX632604 IHC-P Image

SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) detects SARS-CoV-2 (COVID-19) spike protein by immunohistochemical analysis of SARS-CoV-2 infected human placenta (left) and normal human placenta (right).

The IHC-P was performed by HISTOWIZ.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604

GTX632604 ICC/IF Image

SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] detects SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] protein by immunofluorescent analysis.
Sample: Mock and transfected 293T cells were fixed in 4% paraformaldehyde at RT for 15 min.
Green:SARS-CoV-2 (COVID-19) spike protein stained by SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:1000.
Blue: Fluoroshield with DAPI (GTX30920).

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis performed by coating plate with recombinant SARS-CoV-2 (COVID-19) Spike (L18F,..., K417T, E484K, N501Y, D614G,...,V987P)(ECD), His tag (active) (B.1.1.28) (GTX136091-pro) and SARS-CoV-2 (COVID-19) Spike (ECD) protein, His tag (active) (WT) (GTX135972-pro) (4000-62.5 ng/mL). Coated protein was probed with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (1 μg/mL). Mouse IgG antibody (HRP) (GTX213111-01) (1:10000) was used to detect bound primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of non-transfected and transfected 293T whole cell extracts using GTX632604 as capture antibody at concentration of 5 μg/mL and GTX135360 as detection antibody at concentration of 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604

GTX632604 WB Image

SARS-CoV-2 (COVID-19) Spike (del69-70,del144,N501Y,A570D,D614G,...,D1118H) (ECD) Protein, His tag (GTX136059-pro, 0.25 μg) was separated by 12% SDS-PAGE, and the membrane was blotted with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:5000. The HRP-conjugated anti-mouse IgG antibody (GTX213111-01) was used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 spike (trimer) protein using antibodies as below.
Capture: SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (5 μg/mL)
Detection: SARS-CoV-2 (COVID-19) Spike S2 antibody [HL1038] (GTX635910) (1 μg/mL).

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 (COVID-19) Spike S2 (ECD) protein, human IgG Fc tag (GTX01559-pro) using antibodies as below.
Capture: SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (5 μg/mL)
Detection: Human IgG antibody (HRP) (1:200000 )

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC (Paraffin sections) (IHC-P). GTX632604

GTX632604 IHC-P Image

SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) detects SARS-CoV-2 (COVID-19) spike protein by immunohistochemical analysis of SARS-CoV-2 infected human lung.

The IHC-P was performed by HISTOWIZ.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant Spike ECD protein(s) derived from different strains of SARS-CoV-2 virus (ie., Wild type; B.1.1.7 alpha variant; B.1.351 beta variant; P.1 gamma variant; B1.617.2 delta variant) using antibodies as below.

Capture: SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (5 μg/mL)
Detection: SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1003] (GTX635792) (1 μg/mL)

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 (COVID-19) Spike S2 (ECD) protein, human IgG Fc tag (GTX01559-pro) using antibodies as below.
Capture: SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (5 μg/mL)
Detection: Goat Anti-Human IgG antibody (HRP) (1:200000)

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604

GTX632604 WB Image

SARS-CoV-2 (COVID-19) Spike ( L18F,..., K417N, E484K, N501Y,...)(ECD) Protein, His tag (active) (GTX136061-pro, 0.2 μg) was separated by 12% SDS-PAGE, and the membrane was blotted with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:5000. The HRP-conjugated anti-mouse IgG antibody (GTX213111-01) was used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 spike (trimer) protein using antibodies as below.
Capture: SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (5 μg/mL)
Detection: SARS-CoV-2 (COVID-19) Spike S1 antibody [HL263] (GTX635672) (1 μg/mL).

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 spike (trimer) protein using antibodies as below.
Capture: SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (5 μg/mL)
Detection: SARS-CoV-2 (COVID-19) Spike RBD antibody [HL1003] (GTX635792) (1 μg/mL).

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 (COVID-19) Spike S2 (T716I, S982A, D1118H Mutant) (ECD) protein, His tag (GTX136023-pro), SARS-CoV-2 (COVID-19) Spike S2 (ECD) protein, mouse IgG Fc tag (GTX135684-pro), and SARS-CoV-2 (COVID-19) Spike S2 (ECD) protein, human IgG Fc tag (GTX01559-pro) using SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) as capture antibody at concentration of 5 μg/mL and SARS-CoV-2 (COVID-19) Spike S2 antibody [HL1038] (GTX635910) as detection antibody at concentration of 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 (COVID-19) Spike S2 (T716I, S982A, D1118H Mutant) (ECD) protein, His tag (GTX136023-pro) and SARS-CoV-2 (COVID-19) Spike S2 (ECD) protein, human IgG Fc tag (GTX01559-pro) using SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) as capture antibody at concentration of 5 μg/mL and SARS-CoV-2 (COVID-19) Spike S2 antibody [HL1039] (GTX635911) as detection antibody at concentration of 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis performed by coating plate with recombinant SARS-CoV-2 (COVID-19) Spike (ECD) Protein, B.1.1.529 / Omicron variant, His tag (GTX136780-pro) (29.71-0.46 nM). Coated protein was probed with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (1 μg/mL). Goat anti-mouse IgG antibody (HRP) (GTX213111-01) (1:10000) was used to detect bound primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis performed by coating plate with recombinant full-length SARS-CoV-2 (501.V1) spike protein, SARS-CoV-2 (501.V2) spike protein and SARS-CoV-2 spike protein (4000-62.5 ng/mL). Coated protein was probed with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (1 μg/mL). Mouse IgG antibody (HRP) (GTX213110-01) (1:10000) was used to detect bound primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 (COVID-19) Spike S2 (T716I, S982A, D1118H Mutant) (ECD) protein, His tag (GTX136023-pro) using SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) as capture antibody at concentration of 5 μg/mL and SARS-CoV-2 (COVID-19) Spike S2 antibody [HL237] (GTX635693) as detection antibody at concentration of 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis was performed by coating the plate with recombinant SARS-CoV-2 (COVID-19) Spike (ECD) Protein, Omicron / BA.4 / BA.5 variant, His tag (GTX137113-pro) (28.78-0.45 nM). Coated protein was probed with the specified SARS-CoV-2 (COVID-19) Spike S1 antibodies (1 μg/mL). Goat anti-rabbit IgG antibody (HRP) (GTX213110-01) (1:10000) or goat anti-mouse IgG antibody (HRP) (GTX213111-01) (1:10000) were used to detect the bound primary antibodies.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604

GTX632604 ICC/IF Image

SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] detects SARS-CoV-2 by immunofluorescent analysis.
Sample: Vero E6 cells were infected with SARS-CoV-2 (MOI of 1) and fixed with chilled methanol/acetone.
Green: SARS-CoV-2 infected Vero E6 cells stained by SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604).
Blue: Nuclei were counterstained with DAPI.

*From Zheng Z, et al. bioRxiv(2020). Shown under license agreement

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC-P (cell pellet) (IHC-P (cell pellet)). GTX632604

GTX632604 IHC-P (cell pellet) Image

SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] detects SARS-CoV / SARS-CoV-2 (COVID-19) spike protein by immunohistochemical analysis.
Sample: Paraffin-embedded SARS-CoV-2 (COVID-19) Spike FFPE Cell Pellet Block.
Red: SARS-CoV / SARS-CoV-2 (COVID-19) spike stained by SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:1000.
Green: SARS-CoV-2 (COVID-19) spike stained by SARS-CoV-2 (COVID-19) spike antibody (GTX135356) diluted at 1:1000.
Blue: Fluoroshield with DAPI (GTX30920).
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 spike (trimer) protein using antibodies as below.
Capture: SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (5 μg/mL)
Detection: SARS-CoV-2 (COVID-19) Spike S1 antibody [HL13402] (GTX635713) (1 μg/mL).

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant full-length SARS-CoV-2 spike (trimer) protein using SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) as capture antibody at concentration of 5 μg/mL and SARS-CoV-2 (COVID-19) Spike RBD antibody (GTX135709) as detection antibody at concentration of 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 (COVID-19) Spike S2 (ECD) protein, human IgG Fc tag (GTX01559-pro) using SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) as capture antibody at concentration of 5 μg/mL and Human IgG antibody (HRP) (1:200000) as detection antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC (Paraffin sections) (IHC-P). GTX632604

GTX632604 IHC-P Image

SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] detects SARS-CoV-2 (COVID-19) spike protein by immunohistochemical analysis of infected human placenta.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis performed by coating plate with recombinant Spike ECD protein(s) derived from different strains of SARS-CoV-2 virus (ie., Wild type; B1.617.2 delta variant) (29.71-0.46 nM). Coated protein was probed with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (1 μg/mL). Goat anti-mouse IgG antibody (HRP) (GTX213111-01) (1:10000) was used to detect bound primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant Spike ECD protein(s) derived from different strains of SARS-CoV-2 virus (ie., Wild type; B.1.1.7 alpha variant; B.1.351 beta variant; P.1 gamma variant; B1.617.2 delta variant) using antibodies as below.

Capture: SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (5 μg/mL)
Detection: SARS-CoV-2 (COVID-19) Spike S1 antibody [HL263] (GTX635672) (1 μg/mL)

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Sandwich ELISA detection of recombinant SARS-CoV-2 (COVID-19) Spike (ECD) protein, His tag (active) (GTX135972-pro) using antibodies as below.

Capture: SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (5 μg/mL)
Detection: SARS-CoV-2 (COVID-19) Spike S2 antibody [HL1038] (GTX635910) (1 μg/mL)

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604

GTX632604 WB Image

Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 5% SDS-PAGE, and the membrane was blotted with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:5000. The HRP-conjugated anti-mouse IgG antibody (GTX213111-01) was used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604

GTX632604 WB Image

Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 5% SDS-PAGE, and the membrane was blotted with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:5000. The HRP-conjugated anti-mouse IgG antibody (GTX213111-01) was used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604

GTX632604 WB Image

SARS-CoV-2 (COVID-19) Spike (ECD) Protein, B.1.1.529 / Omicron variant, His tag (1 μg, GTX136780-pro) were separated by 12% SDS-PAGE, and the membrane was blotted with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:5000. The HRP-conjugated anti-mouse IgG antibody (GTX213111-01) was used to detect the primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in ELISA (ELISA). GTX632604

GTX632604 ELISA Image

Indirect ELISA analysis performed by coating plate with recombinant SARS-CoV-2 (COVID-19) Spike ( L18F,..., K417N, E484K, N501Y,...)(ECD) Protein, His tag (active) (South Africa variant) (GTX136061-pro) and SARS-CoV-2 (COVID-19) Spike (ECD) protein, His tag (active) (GTX135972-pro) (4000-62.5 ng/mL). Coated protein was probed with SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) (1 μg/mL). Mouse IgG antibody (HRP) (GTX213110-01) (1:10000) was used to detect bound primary antibody.

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604

GTX632604 ICC/IF Image

The data was published in the 2022 in Int J Mol Sci. PMID: 35805887

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604

GTX632604 ICC/IF Image

The data was published in the 2022 in Int J Mol Sci. PMID: 35805887

Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604

GTX632604 WB Image

The data was published in the 2020 in Sci Rep. PMID: 33318562

Application Reference

Inoue T et al. iScience 2024; 27 (4) : 109363 Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies.
Lin CH et al. Int J Mol Sci 2024; 25 (5) Inhibitory Efficacy of Main Components of Scutellaria baicalensis on the Interaction between Spike Protein of SARS-CoV-2 and Human Angiotensin-Converting Enzyme II.
W-F Tang et al. Antimicrob Agents Chemother 2024; : e0095623 BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir
Application : WB
S Zorad et al. Physiol Res 2024; 73 : 27-35 Angiotensin I and II Stimulate Cell Invasion of SARS-CoV-2: Potential Mechanism via Inhibition of ACE2 Arm of RAS
Application : WB
S Clever et al. Viruses 2024; 16 (3) : 417 Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection
Application : WB
Submit a Reference

REVIEW

SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] Cat. No. GTX632604

Rating ( Average 5 based on 10 users reviews)
Application
Western Blot(WB) ( Average 5 based on 2 users reviews)
Immunocytochemistry/ Immunofluorescence(ICC/IF) ( Average 5 based on 3 users reviews)
IHC (Paraffin sections)(IHC-P) ( Average 5 based on 3 users reviews)
Flow cytometry(FACS) ( Average 5 based on 1 users reviews)
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC (Paraffin sections) (IHC-P). GTX632604
Date : Anonymous submitted on 07-Mar-2022
Score :
Application Tested : IHC-P
Sample : Huma skin tissue specimen
Blocking : 0.3% H2O2 meta, RT, 0.5Hr
Fixation : 10% formalin
Permeabilization /Antigen retrieval : Citrate buffer (ph 6.0)
Primary Antibody : 1:500, 4°C, > 12Hr
Lane Description : Eczema after vaccination. The patient was COVID-19 negative. The signals were accumulated spike proteins which have been produced after mRNA vaccination.
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC (Paraffin sections) (IHC-P). GTX632604
Date : Anonymous submitted on 02-Aug-2020
Score :
Application Tested : IHC-P
Sample Species : SARS-CoV-2
Sample : Human placenta tissue
Fixation : neutral buffered formalin, 25°C, 24Hr
Permeabilization /Antigen retrieval : Citrate buffer pH6, 97°C, 0.3Hr
Primary Antibody : 1:100, 25°C, 0.5Hr
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Flow cytometry (FACS). GTX632604
Date : Anonymous submitted on 14-Jul-2020
Score :
Application Tested : FACS
Sample Species : SARS-CoV-2
Sample : Vero E6 cells infected with SARS-CoV-2 USA-WA1/2020
Fixation : 4% formaldehyde in PBS
Permeabilization /Antigen retrieval : BD Cytofix/Cytoperm
Primary Antibody : 1:100, 25°C, 0.5Hr
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in IHC (Paraffin sections) (IHC-P). GTX632604
Date : Anonymous submitted on 21-Jun-2020
Score :
Application Tested : IHC-P
Sample Species : SARS-CoV-2
Sample : Human lung tissue
Blocking : 2% BSA + 5% donkey serum + 0.15% PBST, 25°C, 1Hr
Permeabilization /Antigen retrieval : 1% Triton, Sodium Citrate Buffer
Primary Antibody : 1:500, 4°C, 16Hr
Figure Note : Green: SARS-CoV-2 (COVID-19) spike stained by SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604).
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604
Date : Anonymous submitted on 21-Jun-2020
Score :
Application Tested : ICC/IF
Sample Species : SARS-CoV-2
Sample : SARS-CoV-2 FL spike transfected HeLa cells
Primary Antibody : 1μg/ml, 4°C, 16Hr
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604
Date : Mohamed Gadalla submitted on 19-Jun-2020
Score :
Application Tested : WB
Sample Species : SARS-CoV-2
Sample : 293T cells
Amount used : 25 μg
Blocking : 5% non-fat dry milk in PBST, 25°C, 1Hr
Primary Antibody : 1:1000, 4°C, 16Hr
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604
Date : Anonymous submitted on 17-Jun-2020
Score :
Application Tested : ICC/IF
Sample Species : SARS-CoV-2
Sample : SARS-CoV-2 spike transfected 293T cells
Fixation : 4% PFA, 25°C, 0.5Hr
Primary Antibody : 1:200, 1°C, 25Hr
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9]. GTX632604
Date : Anonymous submitted on 31-Mar-2020
Score :
Sample Species : SARS-CoV
Sample : SARS-CoV infected 293T cells
Amount used : 10 μg
Blocking : BSA, 1Hr
Primary Antibody : 1:1000, 25°C, 1Hr
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX632604
Date : Anonymous submitted on 10-Mar-2020
Score :
Application Tested : ICC/IF
Sample Species : SARS-CoV-2
Sample : BHK-21 transfected with full-length SARS-CoV-2 spike
Fixation : PFA, 0.5Hr
Primary Antibody : 1:2000, 4°C, 4Hr
Figure Note : Green: SARS-CoV-2 (COVID-19) spike stained by SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604).
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] used in Western Blot (WB). GTX632604
Date : Anonymous submitted on 01-Mar-2020
Score :
Application Tested : WB
Sample Species : SARS-CoV, SARS-CoV-2
Sample : SARS-CoV / SARS-CoV-2 infected Caco-2 cells
Amount used : 20 μg
Blocking : 5% milk in PBST, 20°C, 0.5Hr
Primary Antibody : 1:1000, 4°C, 16Hr
Submit a Review
Application Reference
Inoue T et al. iScience 2024; 27 (4):109363 Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies.
Lin CH et al. Int J Mol Sci 2024; 25 (5) Inhibitory Efficacy of Main Components of Scutellaria baicalensis on the Interaction between Spike Protein of SARS-CoV-2 and Human Angiotensin-Converting Enzyme II.
W-F Tang et al. Antimicrob Agents Chemother 2024;:e0095623 BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir
Application : WB
S Zorad et al. Physiol Res 2024; 73:27-35 Angiotensin I and II Stimulate Cell Invasion of SARS-CoV-2: Potential Mechanism via Inhibition of ACE2 Arm of RAS
Application : WB
S Clever et al. Viruses 2024; 16 (3):417 Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection
Application : WB
Mu?oz-Al?a M? et al. mBio 2024; 15 (2):e0292823 Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
Zhang F et al. mBio 2024; 15 (2):e0167223 SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity.
Lee S et al. NPJ Vaccines 2024; 9 (1):34 Assessing the impact of mRNA vaccination in chronic inflammatory murine model.
Tsumita T et al. Aging Cell 2024; 23 (2):e14050 Viral uptake and pathophysiology of the lung endothelial cells in age-associated severe SARS-CoV-2 infection models.
Bolland W et al. J Virol 2024; 98 (1):e0135123 High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1.
Limanaqi F et al. Biol Res 2024; 57 (1):2 Alpha-synuclein dynamics bridge Type-I Interferon response and SARS-CoV-2 replication in peripheral cells.
T Iida et al. Research Square 2024; High-throughput Light-induced Immunoassay under One-minute Antibody-coating with Energy Saving Nanoparticle-imprinted Substrate
Zuo Y et al. EMBO Rep 2023; 24 (4):e56374 Vitamin C promotes ACE2 degradation and protects against SARS-CoV-2 infection.
Normandin E et al. J Neuropathol Exp Neurol 2023; 82 (4):283-295 Neuropathological features of SARS-CoV-2 delta and omicron variants.
Bhargava A et al. iScience 2023; 26 (12):108449 Transcriptomic analysis of sorted lung cells revealed a proviral activity of the NF-κB pathway toward SARS-CoV-2.
Fujita S et al. J Virol 2023; 97 (10):e0099023 Determination of the factors responsible for the tropism of SARS-CoV-2-related bat coronaviruses to Rhinolophus bat ACE2.
Kimura I et al. J Virol 2023; 97 (10):e0101123 Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics.
A Kachko et al. Vaccine 2023; S0264-410X (23):01498-6 Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models
Application : WB
M Nogami et al. Research Square 2023; Anti-Spike Protein Antibody Immunoreactivity Is Widely Expressed in Human Lymph Nodes with or without Pfizer-BioNTech or Moderna mRNA Vaccination in Non-Infected Individuals
Carvalhal F et al. Molecules 2023; 28 (20) Evaluation of the Cytotoxic and Antiviral Effects of Small Molecules Selected by In Silico Studies as Inhibitors of SARS-CoV-2 Cell Entry.
L?cuyer D et al. Front Immunol 2023; 14:1270081 The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.
Zhang P et al. Proc Natl Acad Sci U S A 2023; 120 (29):e2305896120 Increased neutralization potency and breadth elicited by a SARS-CoV-2 mRNA vaccine forming virus-like particles.
Streblow DN et al. Nat Commun 2023; 14 (1):7062 Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology.
Cui Q et al. MedComm (2020) 2023; 4 (5):e400 The Apolipoprotein E neutralizing antibody inhibits SARS-CoV-2 infection by blocking cellular entry of lipoviral particles.
CF Yang et al. J Biomed Sci 2023; Human ACE2 protein is a molecular switch controlling the mode of SARS-CoV-2 transmission
Cottignies-Calamarte A et al. STAR Protoc 2023; 4 (4):102593 Protocol to detect infectious SARS-CoV-2 at low levels using in situ hybridization techniques.
Ahmed N et al. Viruses 2023; 15 (9) microRNA-185 Inhibits SARS-CoV-2 Infection through the Modulation of the Host's Lipid Microenvironment.
Sauve F et al. EBioMedicine 2023; 96:104784 Long-COVID cognitive impairments and reproductive hormone deficits in men may stem from GnRH neuronal death.
C Di Primio et al. PNAS Nexus 2023; 2 (9):pgad282 Severe acute respiratory syndrome coronavirus 2 infection leads to Tau pathological signature in neurons
Application : WB
TR Ullah et al. Nat Commun 2023; 14 (1):5666 Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection
Application : ICC/IF
N Ahmed et al. Viruses 2023; 15 (9):1921 microRNA-185 Inhibits SARS-CoV-2 Infection through the Modulation of the Host’s Lipid Microenvironment
Application : WB
Vaddadi K et al. Am J Physiol Cell Physiol 2023; 325 (2):C420-C428 Cellular microRNAs target SARS-CoV-2 spike protein and restrict viral replication.
Swain J et al. iScience 2023; 26 (8):107384 F-actin nanostructures rearrangements and regulation are essential for SARS-CoV-2 particle production in host pulmonary cells.
Narayan R et al. Cell Rep Med 2023; 4 (8):101127 Picolinic acid is a broad-spectrum inhibitor of enveloped virus entry that restricts SARS-CoV-2 and influenza A virus in?vivo.
T Deckert-Gaudig et al. ChemRxiv 2023; Identification of RNA-containing virus particles using a triple correlative morphological and microscopic approach
Application : ICC/IF
F Hornung et al. Int J Obes (Lond) 2023; Thoracic adipose tissue contributes to severe virus infection of the lung
Application : IHC-Fr
Sandra E. Reznik et al. Biomolecules 2023; 13 (8):1224 SARS-CoV-2 Infection in Unvaccinated High-Risk Pregnant Women in the Bronx, NY, USA Is Associated with Decreased Apgar Scores and Placental Villous Infarcts
M Azarias Da Silva et al. Sci Adv 2023; 9 (31):eadg2122 Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti–SARS-CoV-2 antibodies in the absence of CXCL13
Application : FACS
Zhang F et al. bioRxiv 2023; SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity.
Sayedahmed EE et al. Mol Ther Methods Clin Dev 2023; 30:194-207 Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine.
Yang J et al. Nat Microbiol 2023; 8 (1):121-134 Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2.
Xu D et al. Nature 2023; 619 (7971):819-827 PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection.
Pillai S et al. Res Sq 2023; A Novel Viral Assembly Inhibitor Blocks SARS-CoV-2 Replication in Airway Epithelial Cells.
Kuzmina A et al. Heliyon 2023; 9 (6):e16750 Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity.
Diray-Arce J et al. Cell Rep Med 2023; 4 (6):101079 Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients.
Zhang YM et al. Natl Sci Rev 2023; 10 (5):nwac034 Clinicopathological and immunological features of new onset kidney disease: a rare event after SARS-CoV-2 vaccination.
2023; Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity
Application : WB
PS Sung et al. EMBO Mol Med 2023;:e16351 Inhibition of SARS-CoV-2-mediated thromboinflammation by CLEC2.Fc
Application : ELISA
Alena Reguzova et al. Research Square 2023; A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge
Application : WB
SB Park et al. Commun Biol 2023; 6 (1):556 SARS-CoV-2 omicron variants harbor spike protein mutations responsible for their attenuated fusogenic phenotype
Application : ICC/IF
Asiedu SO et al. Int J Mol Sci 2023; 24 (8) Mycolactone: A Broad Spectrum Multitarget Antiviral Active in the Picomolar Range for COVID-19 Prevention and Cure.
Satish Pillai et al. Research Square 2023; A Novel Viral Assembly Inhibitor Blocks SARS-CoV-2 Replication in Airway Epithelial Cells
Application : WB
L Lebrun et al. Acta Neuropathol Commun 2023; SARS-Cov-2 infection and neuropathological findings: a report of 18 cases and review of the literature
Application : IHC-P
Lorenzo, M.M. et al. Biology and Life Sciences, Virology 2023; Vaccinia Virus Strain Mva Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models
Application : WB
Swain LA et al. Hepatol Commun 2023; 7 (4) Acute severe hepatitis as a presenting symptom in clinically stable patients admitted with SARS-CoV-2 Omicron infection.
Application : IHC-P
Mohammad TSH et al. Int J Mol Sci 2023; 24 (6) In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity.
Application : ICC/IF
Metzler M et al. Mol Cell Proteomics 2023;:100537 SARS-CoV-2 variants show different host cell proteome profiles with delayed immune response activation in Omicron-infected cells.
Application : ICC/IF
Horndler L et al. Front Immunol 2023; 14:1157263 Decreased breadth of the antibody response to the spike protein of SARS-CoV-2 after repeated vaccination.
Application : ICC/IF
Bussani R et al. J Pathol 2023; 259 (3):254-263 Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19.
Application : IHC-P
Furusawa Y et al. EBioMedicine 2023; 91:104561 In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters.
Application : WB
Luo Y et al. Cell Discov 2023; 9 (1):40 High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2
Application : WB
Piranej S et al. bioRxiv 2023; Rolosense: Mechanical detection of SARS-CoV-2 using a DNA-based motor.
Meseguer S et al. Front Microbiol 2023; 14:1066493 SARS-CoV-2-encoded small RNAs are able to repress the host expression of SERINC5 to facilitate viral replication.
Application : WB
Brogna C et al. Int J Mol Sci 2023; 24 (4) Analysis of Bacteriophage Behavior of a Human RNA Virus, SARS-CoV-2, through the Integrated Approach of Immunofluorescence Microscopy, Proteomics and D-Amino Acid Quantification.
Application : ICC/IF
Ham Y et al. Biosens Bioelectron 2023; 227:115169 The SpACE-CCM: A facile and versatile cell culture medium-based biosensor for detection of SARS-CoV-2 spike-ACE2 interaction.
Application : Neutralizing/Inhibition
Massimo M et al. Brain 2023; 146 (3):1175-1185 Haemorrhage of human foetal cortex associated with SARS-CoV-2 infection.
Application : IHC-Fr
Wu CT et al. Cell 2023; 186 (1):112-130.e20 SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming.
Application : IHC-Fr
Normandin E et al. Nat Commun 2023; 14 (1):574 High-depth sequencing characterization of viral dynamics across tissues in fatal COVID-19 reveals compartmentalized infection.
Fraternale A et al. FASEB J 2023; 37 (2):e22741 Targeting SARS-CoV-2 by synthetic dual-acting thiol compounds that inhibit Spike/ACE2 interaction and viral protein production.
Zhou Y et al. Nat Biotechnol 2023; 41 (1):128-139 A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets.
Application : ICC/IF
Giannakopoulos S et al. PLoS Pathog 2023; 19 (5):e1011409 In vitro evidence against productive SARS-CoV-2 infection of human testicular cells: Bystander effects of infection mediate testicular injury.
Application : ICC/IF
Porter LM et al. Heliyon 2023; 9 (3):e14383 Cigarette smoke preferentially induces full length ACE2 expression in differentiated primary human airway cultures but does not alter the efficiency of cellular SARS-CoV-2 infection.
Application : ICC/IF
Zanon M et al. World J Gastroenterol 2023; 29 (1):200-220 Liver pathology in COVID-19 related death and leading role of autopsy in the pandemic.
Roessler J et al. Biomedicines 2023; 11 (11) SARS-CoV-2 and Epstein-Barr Virus-like Particles Associate and Fuse with Extracellular Vesicles in Virus Neutralization Tests.
Hagelauer E et al. Viruses 2023; 15 (12) Tetherin Restricts SARS-CoV-2 despite the Presence of Multiple Viral Antagonists.
Stewart H et al. EMBO Rep 2023; 24 (12):e57224 Tetherin antagonism by SARS-CoV-2 ORF3a and spike protein enhances virus release.
Styles CT et al. EMBO Mol Med 2023; 15 (12):e17932 Propylene glycol inactivates respiratory viruses and prevents airborne transmission.
Angioni R et al. Cell Rep Med 2023; 4 (11):101266 RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity.
Dey D et al. Nat Commun 2023; 14 (1):8358 A single C-terminal residue controls SARS-CoV-2 spike trafficking and incorporation into VLPs.
Giannakopoulos S et al. bioRxiv 2022; In vitro evidence against productive SARS-CoV-2 infection of human testicular cells: Bystander effects of infection mediate testicular injury.
Rinschen MM et al. Sci Signal 2022; 15 (762):eabo7940 VPS34-dependent control of apical membrane function of proximal tubule cells and nutrient recovery by the kidney.
T Tanikawa et al. Molecules 2022; 27 (17):5405 Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2
Application : IHC-P
Prahl M et al. Nat Commun 2022; 13 (1):4422 Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy.
Application : WB
Tsuji S et al. Nat Aging 2022; 2 (2):115-124 SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response.
Cappelletto A et al. Front Cardiovasc Med 2022; 9:1013262 SARS-CoV-2 Spike protein activates TMEM16F-mediated platelet procoagulant activity.
Application : WB
Mu?oz-Al?a M? et al. bioRxiv 2022; Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants.
Application : WB
Reyes S et al. Sens Diagn 2022; 1 (6):1198-1208 Metal organic framework encapsulated tamavidin-Gluc reporter: application in COVID-19 spike antigen bioluminescent immunoassay.
Biering SB et al. Nat Commun 2022; 13 (1):7630 SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-β signaling.
Application : ICC/IF
Meyer Zu Natrup C et al. J Clin Invest 2022; 132 (24) Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity.
Application : ICC/IF
Peng R et al. EMBO Rep 2022; 23 (12):e55839 Human ZBP1 induces cell death-independent inflammatory signaling via RIPK3 and RIPK1.
Application : WB
Petros BA et al. Med (N Y) 2022; Multimodal surveillance of SARS-CoV-2 at a university enables development of a robust outbreak response framework.
Gupta RK et al. EMBO J 2022; 41 (22):e111653 Cyclin D3 restricts SARS-CoV-2 envelope incorporation into virions and interferes with viral?spread.
Application : WB
Prout A et al. Vaccine 2022; 40 (37):5529-5536 Functional profiling of Covid 19 vaccine candidate by flow virometry.
Application : FACS
Takeda R et al. Sci Rep 2022; 12 (1):14050 Antiviral effect of cetylpyridinium chloride in mouthwash on SARS-CoV-2.
Application : WB
Su P et al. Mol Brain 2022; 15 (1):71 Development of a novel peptide to prevent entry of SARS-CoV-2 into lung and olfactory bulb cells of hACE2 expressing mice.
Application : WB, IP
Narayan R et al. J Hosp Infect 2022; 129:17-21 Efficient elimination of airborne pathogens: a study on?aerosolized Mycobacterium tuberculosis and SARS-CoV-2 using ZeBox technology.
Application : ICC/IF
Mei S et al. Front Immunol 2022; 13:911164 Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.
Application : WB
Macedo S et al. Eur Thyroid J 2022; 11 (4) Detection of SARS-CoV-2 infection in thyroid follicular cells from a COVID-19 autopsy series.
Application : IHC-P
Gao SY et al. Front Immunol 2022; 13:1038562 Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern.
Chen YT et al. Front Immunol 2022; 13:1080897 Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model.
Ogura H et al. Nat Commun 2022; 13 (1):7063 Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19.
Kimura I et al. iScience 2022; 25 (12):105720 The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant.
Kim K et al. Front Immunol 2022; 13:1020165 Translation suppression underlies the restrained COVID-19 mRNA vaccine response in the high-risk immunocompromised group.
Lista MJ et al. J Virol 2022; 96 (23):e0125022 The P681H Mutation in the Spike Glycoprotein of the Alpha Variant of SARS-CoV-2 Escapes IFITM Restriction and Is Necessary for Type I Interferon Resistance.
Nasser H et al. STAR Protoc 2022; 3 (4):101773 Monitoring fusion kinetics of viral and target cell membranes in living cells using a SARS-CoV-2 spike-protein-mediated membrane fusion assay.
Lu Y et al. Mol Biol Cell 2022; 33 (14):ar147 SARS-CoV-2 down-regulates ACE2 through lysosomal degradation.
Tan TS et al. J Virol 2022; 96 (20):e0116222 Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike.
Kiyan Y et al. Sci Rep 2022; 12 (1):16878 Calcium dobesilate reduces SARS-CoV-2 entry into endothelial cells by inhibiting virus binding to heparan sulfate.
Weil T et al. JACS Au 2022; 2 (9):2187-2202 Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses.
Kumar CS et al. ACS Infect Dis 2022; 8 (10):2119-2132 Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells.
Vanhulle E et al. Front Cell Infect Microbiol 2022; 12:989534 Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern.
Aicher SM et al. J Virol 2022; 96 (14):e0060822 Species-Specific Molecular Barriers to SARS-CoV-2 Replication in Bat Cells.
Shimizu K et al. Cancer Sci 2022; 113 (8):2536-2547 A single immunization with cellular vaccine confers dual protection against SARS-CoV-2 and cancer.
Application : ELISA
Bullock HA et al. Front Med (Lausanne) 2022; 9:1099408 Probable vertical transmission of Alpha variant of concern (B.1.1.7) with evidence of SARS-CoV-2 infection in the syncytiotrophoblast, a case report.
Application : IHC-P
Kong W et al. mBio 2022; 13 (6):e0230822 Neuropilin-1 Mediates SARS-CoV-2 Infection of Astrocytes in Brain Organoids, Inducing Inflammation Leading to Dysfunction and Death of Neurons.
Application : ICC/IF, IHC-Fr
Yaron TM et al. Sci Signal 2022; 15 (757):eabm0808 Host protein kinases required for SARS-CoV-2 nucleocapsid phosphorylation and viral replication.
Application : WB
Song J et al. PLoS Biol 2022; 20 (10):e3001805 LRRC15 inhibits SARS-CoV-2 cellular entry in trans.
Application : ICC/IF
Vanslambrouck JM et al. Nat Commun 2022; 13 (1):5943 Enhanced metanephric specification to functional proximal tubule enables toxicity screening and infectious disease modelling in kidney organoids.
Application : IHC-P
John SP et al. Cell Rep 2022; 41 (1):111441 Small-molecule screening identifies Syk kinase inhibition and rutaecarpine as modulators of macrophage training and SARS-CoV-2 infection.
Application : ICC/IF
Agostinis C et al. Front Immunol 2022; 13:957224 SARS-CoV-2 modulates virus receptor expression in placenta and can induce trophoblast fusion, inflammation and endothelial permeability.
Application : ICC/IF
Drewry DH et al. J Med Chem 2022; 65 (19):12860-12882 Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
Application : ICC/IF
Wee LE et al. IDCases 2022; 30:e01611 Detection of viable SARS-CoV-2 in deep respiratory specimens despite negative nasopharyngeal SARS-CoV-2 RT-PCR: Occult COVID-19 as an unsuspected cause of pulmonary infiltrates in immunocompromised patients.
Application : IHC-P
Gourdelier M et al. Sci Rep 2022; 12 (1):14651 Optimized production and fluorescent labeling of SARS-CoV-2 virus-like particles.
Application : WB
Jin JC et al. Pediatr Res 2022; SARS CoV-2 detected in neonatal stool remote from maternal COVID-19 during pregnancy.
Application : ELISA
Hawman DW et al. EBioMedicine 2022; 83:104196 Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in na?ve hamsters compared to ancestral vaccine.
Application : ELISA
Silva-Aguiar RP et al. Biochim Biophys Acta Mol Basis Dis 2022; 1868 (12):166496 SARS-CoV-2 spike protein inhibits megalin-mediated albumin endocytosis in proximal tubule epithelial cells.
Application : ICC/IF, FACS
Tien CF et al. iScience 2022; 25 (8):104709 Glycosylation and S-palmitoylation regulate SARS-CoV-2 spike protein intracellular trafficking.
Application : WB, ICC/IF
Baumeier C et al. Int J Mol Sci 2022; 23 (13) Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series.
Application : IHC-P
Park H et al. Adv Sci (Weinh) 2022; 9 (24):e2105320 TMED3 Complex Mediates ER Stress-Associated Secretion of CFTR, Pendrin, and SARS-CoV-2 Spike.
Application : ICC/IF
Sefik E et al. Nature 2022; 606 (7914):585-593 Inflammasome activation in infected macrophages drives COVID-19 pathology.
Application : ICC/IF
Yamamoto Y et al. Int J Mol Sci 2022; 24 (1) Direct Inhibition of SARS-CoV-2 Spike Protein by Peracetic Acid.
Yamamoto Y et al. Int J Mol Sci 2022; 23 (24) SARS-CoV-2 Spike Protein Mutation at Cysteine-488 Impairs Its Golgi Localization and Intracellular S1/S2 Processing.
Yeh CT et al. Biomedicines 2022; 10 (11) Immunoglobulin Y Specific for SARS-CoV-2 Spike Protein Subunits Effectively Neutralizes SARS-CoV-2 Infectivity and Ameliorates Disease Manifestations In Vivo.
Chan JF et al. Cell Rep Med 2022; 3 (10):100774 A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in?vivo.
Gellenoncourt S et al. J Virol 2022; 96 (19):e0130122 The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants.
Wong YP et al. Int J Environ Res Public Health 2022; 19 (15) SARS-CoV-2 Infection in Pregnancy: Placental Histomorphological Patterns, Disease Severity and Perinatal Outcomes.
Sim JR et al. Cell Rep 2022; 40 (3):111117 Amelioration of SARS-CoV-2 infection by ANO6 phospholipid scramblase inhibition.
Jungwirth J et al. Int J Mol Sci 2022; 23 (13) D,L-Lysine-Acetylsalicylate + Glycine (LASAG) Reduces SARS-CoV-2 Replication and Shows an Additive Effect with Remdesivir.
Wettstein L et al. Commun Biol 2022; 5 (1):681 Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture.
Willett BJ et al. Nat Microbiol 2022; 7 (8):1161-1179 SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.
Mitsunaga M et al. Commun Biol 2022; 5 (1):647 Antimicrobial strategy for targeted elimination of different microbes, including bacterial, fungal and viral pathogens.
Escalera A et al. STAR Protoc 2022; 3 (3):101502 Protocol to isolate and assess spike protein cleavage in SARS-CoV-2 variants obtained from clinical COVID-19 samples.
Zhou Y et al. Res Sq 2022; A comprehensive SARS-CoV-2-human protein-protein interactome network identifies pathobiology and host-targeting therapies for COVID-19.
Kawano H et al. Intern Med 2022; 61 (15):2319-2325 Fulminant Myocarditis 24 Days after Coronavirus Disease Messenger Ribonucleic Acid Vaccination.
R?mi Plan?s et al. Mol Cell 2022; Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells.
Application : IHC-P
Yuchao Chen et al. Sci Adv 2022; 8 (21):eabn3481 Quantitative and ultrasensitive in situ immunoassay technology for SARS-CoV-2 detection in saliva.
Amy R Rappaport et al. Nat Commun 2022; 13 (1):3289 Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection.
Application : WB
Daichi Fujimoto et al. Med Mol Morphol 2022; Sputum characteristics of patients with severe COVID-19: report of two cases with immunocytochemical detection of SARS-CoV-2 spike protein.
Shilei Zhang et al. Cell Mol Immunol 2022; SARS-CoV-2 virus NSP14 Impairs NRF2/HMOX1 activation by targeting Sirtuin 1.
Application : WB
Weijie Zeng et al. Front Cell Infect Microbiol 2022; 12:911313 Evidence of Infection of Human Embryonic Stem Cells by SARS-CoV-2.
Application : WB
Ceri Alan Fielding et al. Elife 2022; 11 SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies.
Application : FACS
Liu Cao et al. Sci Transl Med 2022;:eabm7621 The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants.
Application : IHC-P
Georg Jocher et al. EMBO Rep 2022; 23 (6):e54305 ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion.
Marica Grossegesse et al. J Proteome Res 2022; 21 (2):459-469 Deep Time Course Proteomics of SARS-CoV- and SARS-CoV-2-Infected Human Lung Epithelial Cells (Calu-3) Reveals Strong Induction of Interferon-Stimulated Gene Expression by SARS-CoV-2 in Contrast to SARS-CoV.
Application : WB
Kah-Whye Peng et al. Vaccine 2022; 40 (15):2342-2351 Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.
Application : WB
Ravindra Gupta et al. Res Sq 2022; SARS-CoV-2 Omicron spike mediated immune escape and tropism shift.
Application : WB, ICC/IF
Pehu?n Pereyra Gerber et al. PLoS Pathog 2022; 18 (2):e1010265 A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection.
Application : ICC/IF, FACS
Hang Yang et al. Virol Sin 2022; Cytoplasmic domain and enzymatic activity of ACE2 are not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cells.
Application : WB
Andreia L Pinto et al. Nat Commun 2022; 13 (1):1609 Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium.
Ningfei Ji et al. Emerg Microbes Infect 2022; 11 (1):1115-1125 SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients.
Application : IHC-P
Chan Maung Nyein et al. J Hepatol 2022; Severe de novo liver injury after Moderna vaccination - not always autoimmune hepatitis.
Application : IHC-P
Hiroki Hayashi et al. Curr Res Transl Med 2022; 70 (4):103348 Preclinical study of a DNA vaccine targeting SARS-CoV-2.
Application : ELISA
Daichi Yamasoba et al. Cell 2022; Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
Application : WB
Irina Panina et al. Int J Mol Sci 2022; 23 (9) Molecular Dynamics of DHHC20 Acyltransferase Suggests Principles of Lipid and Protein Substrate Selectivity.
Application : WB
Alice Mac Kain et al. Nat Commun 2022; 13 (1):2442 Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen.
Application : WB
Michael S Nirenberg et al. J Cutan Pathol 2022; Histopathology of persistent long COVID toe: A case report.
E Welsh et al. J Eur Acad Dermatol Venereol 2022; Negative SARS-CoV-2 antibodies in patients with positive immunohistochemistry for spike protein in pityriasis rosea-like eruptions.
Katharina R?ltgen et al. Cell 2022; 185 (6):1025-1040.e14 Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.
Application : IHC-P
Marco A D?az-Salinas et al. Elife 2022; 11 Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike.
Application : WB, FACS, ELISA
Andres Santos et al. Mod Pathol 2022; Absence of SARS-CoV-2 Spike glycoprotein expression in placentas from individuals after mRNA SARS-CoV-2 vaccination.
Application : IHC-P
Bo Meng et al. Nature 2022; Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Application : ICC/IF
Shahzaib Ahamad et al. Front Genet 2022; 13:866474 Anti-Fungal Drug Anidulafungin Inhibits SARS-CoV-2 Spike-Induced Syncytia Formation by Targeting ACE2-Spike Protein Interaction.
Yi-Chung Chang et al. EMBO Mol Med 2022; 14 (4):e15298 A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant.
Application : IHC-P
Veronica Bordoni et al. iScience 2022; 25 (2):103854 The interplay between SARS-CoV-2 infected airway epithelium and immune cells modulates regulatory/inflammatory signals.
Application : ICC/IF
Valeria Garcia-Flores et al. Nat Commun 2022; 13 (1):320 Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2.
Application : IHC-P
Wenrui Guo et al. Life Sci Alliance 2022; 5 (4) Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures.
Application : ICC/IF
Junyuan Cao et al. Viruses 2022; 14 (2) Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19.
Application : WB
Silvia C Trevelin et al. Front Immunol 2022; 13:838328 Disrupted Peyer's Patch Microanatomy in COVID-19 Including Germinal Centre Atrophy Independent of Local Virus.
Application : IHC-P
Yasuo Ariumi et al. J Virol 2022; 96 (6):e0000222 Host Cellular RNA Helicases Regulate SARS-CoV-2 Infection.
Application : WB
Nicola Wanner et al. Nat Metab 2022; 4 (3):310-319 Molecular consequences of SARS-CoV-2 liver tropism.
Application : IHC-P
Anna Riccio et al. Cell Mol Life Sci 2022; 79 (5):227 Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence.
Baris Boyraz et al. Hum Pathol 2022; Placental pathology from COVID-19-recovered (nonacute) patients.
Application : IHC-P
Singh RD et al. Biochim Biophys Acta Mol Basis Dis 2022; 1868 (3):166322 The spike protein of SARS-CoV-2 induces heme oxygenase-1: Pathophysiologic implications.
Application : WB
Dorman LC et al. bioRxiv 2022; A type I interferon response defines a conserved microglial state required for effective neuronal phagocytosis.
Application : ICC/IF
Ramadan AA et al. Viruses 2022; 14 (3) Identification of SARS-CoV-2 Spike Palmitoylation Inhibitors That Results in Release of Attenuated Virus with Reduced Infectivity.
Application : FACS
Magalh?es AC et al. Pathogens 2022; 11 (3) InfectionCMA: A Cell MicroArray Approach for Efficient Biomarker Screening in In Vitro Infection Assays.
Application : ICC/IF
Gehlhausen JR et al. Proc Natl Acad Sci U S A 2022; 119 (9) Lack of association between pandemic chilblains and SARS-CoV-2 infection.
Application : IHC-P
Neuberger M et al. Infection 2022; Duodenal tropism of SARS-CoV-2 and clinical findings in critically ill COVID-19 patients.
Application : IHC-P
Matsuoka K et al. J Biol Chem 2022;:101724 SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a glycoprotein homodimer.
Application : WB
Suzuki R et al. Nature 2022; (Epub) Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
Application : WB, ICC/IF
Kung YA et al. mBio 2022;:e0271721 Acyl-Coenzyme A Synthetase Long-Chain Family Member 4 Is Involved in Viral Replication Organelle Formation and Facilitates Virus Replication via Ferroptosis.
Application : ICC/IF
Kim Y et al. Cell Mol Immunol 2022; (Epub) MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination.
Wan L et al. Nat Metab 2022; (Epub) GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia.
Application : ICC/IF
Fenizia C et al. Microbiol Spectr 2022;:e0150421 Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Tada T et al. Cell Rep 2022; 38 (2):110237 High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals.
Application : WB
Hassler L et al. Clin J Am Soc Nephrol 2021; 16 (11):1755-1765 Evidence For and Against Direct Kidney Infection by SARS-CoV-2 in Patients with COVID-19.
Wen-Fang Tang et al. Biomed J 2021; 44 (3):293-303 Perilla (Perilla frutescens) leaf extract inhibits SARS-CoV-2 via direct virus inactivation.
Application : WB
Benjamin C Jennings et al. FEBS Lett 2021; 595 (13):1758-1767 A weak COPI binding motif in the cytoplasmic tail of SARS-CoV-2 spike glycoprotein is necessary for its cleavage, glycosylation, and localization.
Application : WB, ICC/IF
Patthara Kongsuphol et al. Commun Med (Lond) 2021; 1:46 A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies.
Cheng Wang et al. Cell Stem Cell 2021; 28 (2):331-342.e5 ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response.
Application : ICC/IF
H Stewart et al. bioRxiv 2021; SARS-CoV-2 spike downregulates tetherin to enhance viral spread.
Application : ICC/IF
Xin Yin et al. Cell Rep 2021; 34 (2):108628 MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells.
Application : WB
Luke Lee et al. Res Sq 2021; Quantitative and Ultrasensitive In-situ Immunoassay Technology for SARS-CoV-2 Detection in Saliva.
Armin Bayati et al. J Biol Chem 2021;:100306 SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis.
Application : WB, ICC/IF
Maria Casagrande et al. JAMA Ophthalmol 2021; 139 (4):383-388 Presence of SARS-CoV-2 RNA in the Cornea of Viremic Patients With COVID-19.
Application : IHC-P
Jerzy Osipiuk et al. Nat Commun 2021; 12 (1):743 Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.
Application : ICC/IF
Nanda Kishore Routhu et al. Immunity 2021; A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.
Application : WB
Taha Azad et al. Mol Ther 2021; Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2?S for viral entry.
Application : Neutralizing/Inhibition
Erica D Dawson et al. J Virol Methods 2021;:114111 Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses.
Application : ELISA
Kentaro Uemura et al. Sci Rep 2021; 11 (1):5376 MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2.
Application : ICC/IF
Shahanshah Khan et al. bioRxiv 2021; SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway.
Application : FACS
Ruklanthi de Alwis et al. Mol Ther 2021; 29 (6):1970-1983 A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
Application : WB
Maria Casagrande et al. Br J Ophthalmol 2021; Detection of SARS-CoV-2 genomic and subgenomic RNA in retina and optic nerve of patients with COVID-19.
Application : IHC-P
Jamie M Walker et al. J Neuropathol Exp Neurol 2021; 80 (6):628-631 COVID-19 Patients With CNS Complications and Neuropathologic Features of Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalopathy.
Stefanie Deinhardt-Emmer et al. J Virol 2021; SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction.
Application : ICC/IF
Manuel Hayn et al. Cell Rep 2021; 35 (7):109126 Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities.
Application : WB
Yun Teng et al. Mol Ther 2021; Plant-derived exosomal microRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12.
Application : WB
Toshiki Ebisudani et al. Cell Rep 2021;:109218 Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening.
Application : ICC/IF
Akinari Tsukada et al. Intern Med 2021; 60 (14):2297-2300 A Kidney Transplant Patient Who Died of COVID-19-associated Severe Acute Respiratory Distress Syndrome.
Application : IHC-P
Rianna Vandergaast et al. mSphere 2021; 6 (3):e0017021 IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers.
Application : WB
S?bastien Lyonnais et al. Sci Rep 2021; 11 (1):11885 Atomic force microscopy analysis of native infectious and inactivated SARS-CoV-2 virions.
Application : WB
Carolina da S G Pedrosa et al. Stem Cell Res 2021; 54:102436 Non-permissive SARS-CoV-2 infection in human neurospheres.
Application : WB
Jakob Trimpert et al. Cell Rep 2021;:109493 Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding.
Application : WB
Dickson W L Wong et al. Cells 2021; 10 (8) Multisystemic Cellular Tropism of SARS-CoV-2 in Autopsies of COVID-19 Patients.
Application : IHC-P
Caterina Prelli Bozzo et al. Nat Commun 2021; 12 (1):4584 IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro.
Application : WB
Drucilla J Roberts et al. Am J Obstet Gynecol 2021; A standardized definition of placental infection by SARS-CoV-2, a consensus statement from the National?Institutes of Health/Eunice Kennedy Shriver National?Institute of Child Health and Human Development?SARS-CoV-2 Placental Infection Workshop.
Elaine C Chen et al. Cell Rep 2021; 36 (8):109604 Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals.
Abhijith Biji et al. EBioMedicine 2021; 70:103525 Identification of COVID-19 prognostic markers and therapeutic targets through meta-analysis and validation of Omics data from nasopharyngeal samples.
Application : WB
Xiangchuan He et al. Emerg Microbes Infect 2021; 10 (1):1555-1573 A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
Application : ICC/IF
Fabian Zech et al. Nat Commun 2021; 12 (1):6855 Spike residue 403 affects binding of coronavirus spikes to human ACE2.
Application : WB
Shahanshah Khan et al. Elife 2021; 10 SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway.
Application : WB, FACS
Sung-Chan Wei et al. Front Immunol 2021; 12:771011 An Integrated Platform for Serological Detection and Vaccination of COVID-19.
Application : WB, ICC/IF, ELISA
Michihito Sasaki et al. mBio 2021; 12 (4):e0141521 SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity.
Application : IHC-P
Rakesh Kulkarni et al. PLoS One 2021; 16 (9):e0257191 Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters.
Application : WB
Xiaoquan Li et al. PLoS Pathog 2021; 17 (9):e1009898 Ethacridine inhibits SARS-CoV-2 by inactivating viral particles.
Application : ICC/IF
Carmen Mirabelli et al. Proc Natl Acad Sci U S A 2021; 118 (36) Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Application : ICC/IF
Tsuguhisa Nakayama et al. Cell Rep Med 2021; 2 (10):100421 Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers.
Application : IHC-P
Shu Liu et al. Nat Commun 2021; 12 (1):5739 Highly efficient intercellular spreading of protein misfolding mediated by viral ligand-receptor interactions.
Application : WB
Riccardo De Santis et al. J Photochem Photobiol 2021; 8:100082 Rapid inactivation of SARS-CoV-2 with LED irradiation of visible spectrum wavelengths.
Application : WB
Kasopefoluwa Y Oguntuyo et al. mBio 2021; 12 (1) Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.
Application : WB
Hsu-Yu Chen et al. J Virol 2021; 95 (22):e0096621 Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation.
Application : WB
Barbara Storti et al. Comput Struct Biotechnol J 2021; 19:6140-6156 A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells.
Application : WB
Marta De Angelis et al. Biomedicines 2021; 9 (11) Protective Role of Combined Polyphenols and Micronutrients against Influenza A Virus and SARS-CoV-2 Infection In Vitro.
Application : WB
Biering SB et al. bioRxiv 2021; SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-β signaling.
Zhao L et al. MedComm (2020) 2021; SARS-CoV-2 spike protein harnesses SNX27-mediated endocytic recycling pathway.
Application : FACS
Song J et al. bioRxiv 2021; LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry in trans.
Yokoi S. et al. Eur J Dermatol. 2021; 31 (4):568-570 COVID-19-associated livedo and purpura: clinical and histopathological findings.
Application : IHC-P
Kongsuphol P. et al. Communications Medicine 2021; (Epub) A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies.
Zhang Z et al. Cell Death Differ 2021; 28 (9):2765-2777 SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination.
Application : WB
Rosner-Tenerowicz A et al. BMC Pregnancy Childbirth 2021; 21 (1):760 Placental pathology in a pregnant woman with severe COVID-19 and successful ECMO treatment: a case report.
Application : IHC-P
Al-Beltagi S et al. Virulence 2021; 12 (1):2946-2956 Emergent SARS-CoV-2 variants: comparative replication dynamics and high sensitivity to thapsigargin.
Application : ICC/IF
Ohtsuka J et al. iScience 2021; 24 (12):103379 Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2.
Application : WB
Saito A et al. Nature 2021; Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
Application : WB
Kim M et al. Biomedicines 2021; 9 (11) In Vitro Replication Inhibitory Activity of Xanthorrhizol against Severe Acute Respiratory Syndrome Coronavirus 2.
Zhong C et al. NPJ Vaccines 2021; 6 (1):139 Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies.
Application : WB
Xiao Y et al. Cell 2021; 184 (25):6037-6051.e14 A defective viral genome strategy elicits broad protective immunity against respiratory viruses.
Application : IHC-P
Zhao L. et al. MedComm 2021; (Epub) SARS-CoV-2 spike protein harnesses SNX27-mediated endocytic recycling pathway.
Application : ICC/IF
Shue B et al. J Virol 2021; 95 (24):e0059621 Genome-Wide CRISPR Screen Identifies RACK1 as a Critical Host Factor for Flavivirus Replication.
Application : WB
Johnson JE et al. Am J Pathol 2021; (Epub) Coronavirus Disease 2019 (COVID-19) Coronary Vascular Thrombosis: Correlation with Neutrophil but Not Endothelial Activation.
Application : IHC-P
Carter-Timofte ME et al. ACS Infect Dis 2021; 7 (11):3034-3051 Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern.
Application : FACS
Kudose S et al. J Am Soc Nephrol 2021; 32 (11):2958-2969 Longitudinal Outcomes of COVID-19-Associated Collapsing Glomerulopathy and Other Podocytopathies.
Application : IHC-P
Ren H et al. Biol Direct 2021; 16 (1):20 Micronucleus production, activation of DNA damage response and cGAS-STING signaling in syncytia induced by SARS-CoV-2 infection.
Application : WB
Tada T et al. iScience 2021; 24 (11):103341 Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera.
Application : WB
Kim DH et al. Sci Rep 2021; 11 (1):21462 Hemin as a novel candidate for treating COVID-19 via heme oxygenase-1 induction.
Application : ICC/IF
Thyrsted J et al. iScience 2021; 24 (11):103300 Influenza A induces lactate formation to inhibit type I IFN in primary human airway epithelium.
Application : WB
Seo JS et al. Viruses 2021; 13 (8) The Microvillar and Solitary Chemosensory Cells as the Novel Targets of Infection of SARS-CoV-2 in Syrian Golden Hamsters.
Application : IHC-P
Gomes I et al. Lancet Reg Health Am 2021; 2:100046 SARS-CoV-2 infection of the central nervous system in a 14-month-old child: A case report of a complete autopsy.
Application : IHC-P
Uemura K et al. iScience 2021; 24 (10):103120 5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2.
Application : ICC/IF
Navaratnarajah CK et al. J Virol 2021;:JVI0136821 Highly efficient SARS-CoV-2 infection of human cardiomyocytes: spike protein-mediated cell fusion and its inhibition.
Application : WB, ICC/IF, FACS
Cheng YW et al. mBio 2021; 12 (4):e0058721 D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage.
Application : WB
Araujo-Silva CA et al. JAMA Ophthalmol 2021; 139 (9):1015-1021 Presumed SARS-CoV-2 Viral Particles in the Human Retina of Patients With COVID-19.
Application : WB
Dal Ferro M et al. Clin Res Cardiol 2021; (Epub) SARS-CoV-2, myocardial injury and inflammation: insights from a large clinical and autopsy study.
Application : IHC-P
Lam LKM et al. Am J Physiol Lung Cell Mol Physiol 2021; 321 (2):L485-L489 Erythrocytes identify complement activation in patients with COVID-19.
Sasaki M. et al. PLoS Pathog. 2021; 17 (1):e1009233 SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells.
Application : ICC/IF
Tada T et al. mBio 2021; 12 (3):e0069621 Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
Application : WB
Matsuura R et al. Viruses 2021; 13 (5) SARS-CoV-2 Disinfection of Air and Surface Contamination by TiO2 Photocatalyst-Mediated Damage to Viral Morphology, RNA, and Protein.
Application : WB
Wu CT et al. Cell Metab 2021; 33 (8):1565-1576.e5 SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment.
Colson A et al. Am J Pathol 2021; 191 (9):1610-1623 Clinical and in?Vitro Evidence against Placenta Infection at Term by Severe Acute Respiratory Syndrome Coronavirus 2.
Application : IHC-P
Masterson AN et al. Anal Chem 2021; 93 (25):8754-8763 Multiplexed and High-Throughput Label-Free Detection of RNA/Spike Protein/IgG/IgM Biomarkers of SARS-CoV-2 Infection Utilizing Nanoplasmonic Biosensors.
Yang AC et al. Nature 2021; 595 (7868):565-571 Dysregulation of brain and choroid plexus cell types in severe COVID-19.
Application : IHC-P
Higuchi Y et al. Nat Commun 2021; 12 (1):3802 Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2.
Application : IHC-P
Fenizia C et al. Cells 2021; 10 (6) SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2.
Application : WB
Ciccosanti F et al. Antiviral Res 2021; 190:105064 Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection.
Application : WB, ICC/IF
P?rez A et al. Viruses 2021; 13 (4) IgA-Dominant Infection-Associated Glomerulonephritis Following SARS-CoV-2 Infection.
Application : IHC-P
Braga L et al. Nature 2021; 594 (7861):88-93 Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.
Application : ICC/IF
Sui Y et al. JCI Insight 2021; 6 (10) Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques.
Application : IHC-P
Kim YJ et al. Viruses 2021; 13 (4) The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
Application : WB
Di Domenico M et al. Diagnostics (Basel) 2021; 11 (4) Detection of SARS-COV-2 Proteins Using an ELISA Test.
Harbour JC et al. J Immunol 2021; 206 (11):2596-2604 Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein.
Application : WB
Gutmann C et al. Nat Commun 2021; 12 (1):3406 SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care.
Kumar A et al. J Virol 2021; 95 (13):e0026621 SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors.
Roden AC et al. Arch Pathol Lab Med 2021; 145 (7):785-796 Comparison of In Situ Hybridization, Immunohistochemistry, and Reverse Transcription-Droplet Digital Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing in Tissue.
Application : IHC-P
Liu G et al. Nat Microbiol 2021; 6 (4):467-478 ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity.
Application : WB
Huang N et al. Nat Med 2021; 27 (5):892-903 SARS-CoV-2 infection of the oral cavity and saliva.
Application : IHC-P
Dicken SJ et al. bioRxiv 2021; Characterisation of B.1.1.7 and Pangolin coronavirus spike provides insights on the evolutionary trajectory of SARS-CoV-2.
Application : WB
Yamada T. et al. Nat Immunol 2021; (Epub) RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells.
Application : ICC/IF
Winstone H et al. J Virol 2021; 95 (9) The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2.
Application : WB
Monte-Serrano J et al. Dermatol Ther 2021;:e14897 Granuloma annulare triggered by SARS-CoV-2 infection: Immunohistochemical staining.
Application : IHC-P
Azad T et al. Biosens Bioelectron 2021; 180:113122 SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition.
Yeung ML et al. Cell 2021; 184 (8):2212-2228.e12 Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.
Sharma P et al. Clin Kidney J 2021; 14 (Suppl 1):i30-i39 Pathology of COVID-19-associated acute kidney injury.
Application : IHC-P
Cheng Y.W. et al. bioRxiv 2021; (Epub) D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Viral Transmission via Enhanced Furin-mediated Spike Cleavage.
Application : WB
Garc?a-Arriaza J et al. J Virol 2021; (Epub) COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
Application : WB
Jang Y et al. Sci Rep 2021; 11 (1):821 Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2.
Application : ICC/IF
Linehan L et al. Placenta 2021; 104:261-266 SARS-CoV-2 placentitis: An uncommon complication of maternal COVID-19.
Application : IHC-P
Lu-Culligan A et al. medRxiv 2021; (Epub) SARS-CoV-2 infection in pregnancy is associated with robust inflammatory response at the maternal-fetal interface.
Application : IHC-P
Zhou H et al. bioRxiv 2021; (Epub) B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies.
Lamers MM et al. Elife 2021; 10 Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation.
Application : WB
Wang L et al. Theranostics 2021; 11 (2):649-664 Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein.
Application : WB, ICC/IF
Jang Y et al. Int J Mol Sci 2021; 22 (4)
Application : ICC/IF
Di Teodoro G et al. Vet Microbiol 2021; 252:108933 SARS-CoV-2 replicates in respiratory ex vivo organ cultures of domestic ruminant species.
Application : IHC-P
Welsh E et al. Br J Dermatol 2021; (Epub) SARS-CoV-2 Spike Protein Positivity in Pityriasis Rosea-like and Urticaria-like Rashes of COVID-19.
Application : IHC-P
Rebendenne A et al. J Virol 2021; (Epub) SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells.
Application : WB
Ozono S et al. Nat Commun 2021; 12 (1):848 SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity.
Application : WB
Tada T et al. bioRxiv 2021; (Epub) Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies.
Application : WB
Eric Song et al. J Exp Med 2021; 218 (3):e20202135 Neuroinvasion of SARS-CoV-2 in human and mouse brain.
Application : IHC-P
Jana Kr?ger et al. Cell Mol Gastroenterol Hepatol 2020; Drug Inhibition of SARS-CoV-2 Replication in Human Pluripotent Stem Cell-Derived Intestinal Organoids.
Application : ICC/IF
Mirko Cortese et al. Cell Host Microbe 2020; 28 (6):853-866.e5 Integrative Imaging Reveals SARS-CoV-2-Induced Reshaping of Subcellular Morphologies.
Application : ICC/IF
Takuya Tada et al. Cell Rep 2020;:108528 An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.
Application : WB
Carmen Mirabelli et al. bioRxiv 2020; Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19.
Application : ICC/IF
Alberto Priori et al. Front Public Health 2020; 8:575029 The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, Italy.
Application : IHC-P
Katsura H et al. Cell Stem Cell 2020; 27 (6):890-904.e8 Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction.
Nchioua R et al. mBio 2020; 11 (5) SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans.
Cheng YW et al. Cell Rep 2020; 33 (2):108254 Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects.
Conzelmann C et al. J Extracell Vesicles 2020; 9 (1):1808281 Salivary extracellular vesicles inhibit Zika virus but not SARS-CoV-2 infection.
Song E et al. bioRxiv 2020; (Epub) Neuroinvasion of SARS-CoV-2 in human and mouse brain.
Ramani A et al. EMBO J 2020; 39 (20):e106230 SARS-CoV-2 targets neurons of 3D human brain organoids.
Conzelmann C et al. Antiviral Res 2020; 181:104882 An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection.
Chiuppesi F et al. bioRxiv 2020; Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.
Lokugamage KG et al. bioRxiv 2020; (Epub) SARS-CoV-2 is sensitive to type I interferon pretreatment.
Havranek KE et al. Viruses 2020; 12 (12) SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus.
Application : WB
Bernard I et al. Viruses 2020; 13 (1) Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19.
Application : ICC/IF
Vandergaast R et al. bioRxiv 2020; (Epub) Development and validation of IMMUNO-COV?: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2.
Application : WB
Gao C et al. bioRxiv 2020; (Epub) SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors.
Application : WB
Heaton BE et al. bioRxiv 2020; (Epub) SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2.
Application : ICC/IF
Oguntuyo KY et al. medRxiv 2020; (Epub) Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera.
Application : WB
Drayman N et al. bioRxiv 2020; (Epub) Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro.
Application : IHC-P
Olagnier D et al. Nat Commun 2020; 11 (1):4938 SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate.
Application : WB
Dalskov L et al. EMBO Rep 2020;:e51252 SARS-CoV-2 evades immune detection in alveolar macrophages.
Application : WB
Pellegrini L et al. Cell Stem Cell 2020; 27 (6):951-961.e5 SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids.
Application : IHC-P
Li X et al. bioRxiv 2020; (Epub) Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models.
Application : IHC-P
Chiuppesi F et al. Nat Commun 2020; 11 (1):6121 Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform.
Application : FACS
Ng JH et al. Adv Chronic Kidney Dis 2020; 27 (5):365-376 Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19.
Application : IHC-P
Swann H et al. Sci Rep 2020; 10 (1):21877 Minimal system for assembly of SARS-CoV-2 virus like particles.
Application : EM
Kuo-Yen Huang et al. EMBO Mol Med 2020;:e12828 Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
Application : WB
Zhao CL et al. Hum Pathol 2020; (Epub) Pathological findings in the postmortem liver of COVID-19 patients.
Application : IHC-P
Jacob E Valk et al. J Perinatol. 2020;:1-3 Detection of SARS-CoV-2 in placental but not fetal tissues in the second trimester.
Application : IHC-P
Cristiane J Nunes-Santos et al. J Clin Immunol. 2020;:1-10 N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects.
Application : WB
Congwen Wei et al. Nat Metab. 2020; (Epub) HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry.
Application : ICC/IF
Caroline B Plescia et al. J Biol Chem. 2020;:jbc.RA120.016148. SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles.
Application : WB, ICC/IF
Hattori SI et al. mBio 2020; 11 (4) GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.
Application : ICC/IF
Boix-Vilanova J et al. Int J Dermatol 2020; (Epub) Grover-like skin eruption: another cutaneous manifestation in a COVID-19 patient.
Application : IHC-P
Ian Gallicano G et al. Gene Ther 2020; (Epub) Molecular targeting of vulnerable RNA sequences in SARS CoV-2: identifying clinical feasibility.
Application : WB, ICC/IF
Rossana Bussani et al. EBioMedicine 2020;:103104 Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology.
Laura Varela Barca et al. Interact Cardiovasc Thorac Surg 2020; (Epub) An unexplained death after routine cardiac surgery: how long have we dealt with coronavirus disease 2019?
Application : IHC-P
Carolina da S G Pedrosa et al. bioRxiv 2020;:2020.09.11.293951 Non-permissive SARS-CoV-2 infection of neural cells in the developing human brain and neurospheres.
Application : WB, IHC-P
Kumari G Lokugamage et al. J Virol. 2020;:JVI.01410-20 Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.
Application : WB
Hongjie Xia et al. Cell Rep. 2020; 33 (1):108234 Evasion of Type I Interferon by SARS-CoV-2.
Application : WB
Chiuppesi F et al. Res Sq 2020; Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.
Application : FACS
Andina D et al. Pediatr Dermatol 2020; Suspected COVID-19-related reticulated purpura of the soles in an infant.
Application : IHC-P
Szabolcs M et al. Appl Immunohistochem Mol Morphol 2020; Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues.
Application : IHC-P
Thomas Mandel Clausen et al. Cell 2020; S0092-8674 (20):31230-7 SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
Application : FACS
Jakob Matschke et al. Lancet Neurol. 2020; S1474-4422 (20):30308-2 Neuropathology of patients with COVID-19 in Germany: a post-mortem case series.
Application : IHC-P
Kellie J Goodlet et al. Transpl Infect Dis 2020;:e13480 COVID-19 in a Lung Transplant Recipient: Exploring the Diagnostic Role of Circulating Exosomes and the Clinical Impact of Advanced Immunosuppression.
Application : WB
T Gambichler et al. J Eur Acad Dermatol Venereol. 2020; (Epub) SARS-CoV-2 spike protein is present in both endothelial and eccrine cells of a chilblain-like skin lesion.
Application : IHC-P
Alain C Borczuk et al. Mod Pathol. 2020; (Epub) COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City.
Application : IHC-P
Antonio Torrelo et al. Pediatr Dermatol. 2020;:10.1111/pde.14246. Erythema multiforme‐like lesions in children and COVID‐19.
Application : IHC-P
Appelberg S et al. Emerg Microbes Infect 2020; 9 (1):1748-1760 Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells.
Mariano Carossino et al. Arch Virol 2020; 5:1-5 Detection of SARS-CoV-2 by RNAscope ® in situ hybridization and immunohistochemistry techniques.
Application : IHC-P
Christine J Ko et al. J Cutan Pathol . 2020; (Epub) Perniosis during the COVID-19 pandemic: Negative Anti-SARS-CoV-2 Immunohistochemistry in Six Patients and Comparison to Perniosis Before the Emergence of SARS-CoV-2.
Application : IHC-P
Benjamin T Bradley et al. Lancet 2020; S0140-6736 (20):31305-2 Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series.
Application : IHC-P
Satoru Kudose et al. J Am Soc Nephrol 2020;:ASN.2020060802 Kidney Biopsy Findings in Patients with COVID-19.
Application : IHC-P
Bianca Pulinx et al. Eur J Clin Microbiol Infect Dis 2020; 13:1-15 Vertical transmission of SARS-CoV-2 infection and preterm birth.
Application : IHC-P
Laura Prieto-Pérez et al. Mod Pathol 2020; (Epub) Histiocytic Hyperplasia With Hemophagocytosis and Acute Alveolar Damage in COVID-19 Infection.
Application : IHC-P
C Santonja et al. Br J Dermatol 2020; (Epub) COVID-19 Chilblain-Like Lesion: Immunohistochemical Demonstration of SARS-CoV-2 Spike Protein in Blood Vessel Endothelium and Sweat Gland Epithelium in a PCR-negative Patient.
Application : IHC-P
I Colmenero et al. Br J Dermatol 2020; (Epub) SARS-CoV-2 Endothelial Infection Causes COVID-19 Chilblains: Histopathological, Immunohistochemical and Ultraestructural Study of 7 Paediatric Cases.
Application : IHC-P
Clone Reference
Zhiqiang Zheng et al. 2020; (Epub) Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2.
Application : ICC/IF
Kuo-Ming Lip et al. J Virol . 2006; 80 (2):941-50 Monoclonal Antibodies Targeting the HR2 Domain and the Region Immediately Upstream of the HR2 of the S Protein Neutralize in Vitro Infection of Severe Acute Respiratory Syndrome Coronavirus.
Application : WB
Reactivity : SARS Coronavirus
SDS
PBS.pdf

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
ER201-01
 50rxns